Evidence map›Paper›PMID 41194935›Full record

ArticleFrontiers in immunology2025

Development of a machine learning model to predict overall survival for large hepatocellular carcinoma at BCLC stage A or B after curative hepatectomy.

Tai-Xin Yang, Jia-Yong Su, Min-Jun Li, Shuang Shen, Yu Wang, Huan-Nan Wei, Ming-Jian Huang, Qing-Man Qin, You-Yin Ran, Yao-Ting Huang and 4 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tai-Xin Yang *Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Jia-Yong Su *Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Min-Jun Li *Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Shuang Shen *Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Yu WangGuangxi Medical University, , Nanning, China.
Huan-Nan WeiGuangxi Medical University, , Nanning, China.
Ming-Jian HuangGuangxi Medical University, , Nanning, China.
Qing-Man QinGuangxi Medical University, , Nanning, China.
You-Yin RanGuangxi Medical University, , Nanning, China.
Yao-Ting HuangGuangxi Medical University, , Nanning, China.
Jin-Yan HuangGuangxi Medical University, , Nanning, China.
Bang-De XiangDepartment of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Jie ZhangDepartment of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Wen-Feng GongDepartment of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Patients with large hepatocellular carcinoma (LHCC) have a poor prognosis even after curative hepatectomy. This study aimed to develop and validate an interpretable machine learning (ML) model to predict their overall survival (OS). Methods: This study included 2,565 patients with hepatocellular carcinoma (HCC) who underwent curative hepatectomy between January 2014 and December 2021. The LHCC patients were randomly assigned (7:3 ratio) to a training (n=1069) or validation (n=457) group. Independent risk factors for OS were identified using multivariable Cox regression. Eight ML models were developed and compared. The optimal model's interpretability was assessed using Shapley Additive Explanations (SHAP). Results: LHCC patients experienced a considerable reduction in OS (Hazard Ratio, HR: 1.810, 95% Confidence Interval, CI: 1.585-2.068) compared to SHCC patients. Among eight ML models, the gradient boosting machine (GBM) model demonstrated superior performance. In the validation group, the GBM model achieved area under the receiver operating characteristic curve (AUC) values of 0.742, 0.744, and 0.750 for 1-, 3-, and 5-year OS, respectively. These results were comparable with or superior to established postoperative predictive models. The GBM model showed the ability to stratify patients with LHCC into distinct prognostic groups. A web-based calculator was developed for risk score generation. Notably, the GBM model showed enhanced predictive accuracy in patients with a high neutrophil-lymphocyte ratio (C-index: 0.819). Conclusions: The GBM-based model demonstrated the potential to predict prognosis for patients with LHCC after curative hepatectomy. This interpretable model may assist in personalized risk assessment and tailoring postoperative management strategies.

Indexed as

Carcinoma, HepatocellularHepatectomyLiver NeoplasmsMachine LearningAdultAgedFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisRisk AssessmentRisk Factorsgradient boosting machinehepatectomylarge hepatocellular carcinomaoverall survivalSHAP

Identifiers

PMID41194935
PMCPMC12583128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.